Heartseed Inc. (219A.T)
Tokyo · JPY · Healthcare · Biotechnology
¥2,890 (+6.92%) as of
Key statistics
- Market cap
- 66.17B
- P/E (TTM)
- 346.11
- EPS (TTM)
- 8.35
- Dividend yield
- 0.00%
- 52-week range
- 1,365.00 – 2,958.00
- Beta
- -0.75
- Revenue (TTM)
- 3.03B
- Profit margin
- 19.58%
- Analyst target
- ¥3,700
- Volume
- 884.20k
About Heartseed Inc.
Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company's lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Tokyo, Japan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.